Voyager Therapeutics, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 17 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-06-09: Reporting owner SCANGOS GEORGE A; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-06-09: Reporting owner MACKEY CATHERINE J; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-06-09: Reporting owner Hyman Steven; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-06-09: Reporting owner Vitale Nancy; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
VYGR insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-09 | SCANGOS GEORGE A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $3.43 exercise price | $3.43 | 2026-06-11 |
| 2026-06-09 | MACKEY CATHERINE J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $3.43 exercise price | $3.43 | 2026-06-11 |
| 2026-06-09 | Hyman Steven Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 | $3.43 exercise price | $3.43 | 2026-06-11 |
| 2026-06-09 | Vitale Nancy Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $3.43 exercise price | $3.43 | 2026-06-11 |
| 2026-06-09 | Higgins Michael J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $3.43 exercise price | $3.43 | 2026-06-11 |
| 2026-06-09 | Onyia Jude Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $3.43 exercise price | $3.43 | 2026-06-11 |
| 2026-06-09 | GERAGHTY JAMES A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $3.43 exercise price | $3.43 | 2026-06-11 |
| 2026-06-09 | Colon Grace Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 | $3.43 exercise price | $3.43 | 2026-06-11 |
| 2026-06-09 | PIERCE GLENN Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $3.43 exercise price | $3.43 | 2026-06-11 |
| 2026-05-18 holding as of filing | Quinlan Amy Officer (Principal Accounting Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $5.28 exercise price | 2026-05-18 | ||
| 2026-05-18 holding as of filing | Quinlan Amy Officer (Principal Accounting Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $3.68 exercise price | 2026-05-18 | ||
| 2026-02-06 | Ferguson Toby Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +210,000 210,000 owned after | $3.68 exercise price | $3.68 | 2026-02-10 |
| 2026-02-06 | Carter Todd Alfred Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +154,000 154,000 owned after | $3.68 exercise price | $3.68 | 2026-02-10 |
| 2026-02-06 | Swartz Robin Officer (COO & CBO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +210,000 210,000 owned after | $3.68 exercise price | $3.68 | 2026-02-10 |
| 2026-02-06 | Sandrock Alfred Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +402,500 402,500 owned after | $3.68 exercise price | $3.68 | 2026-02-10 |
| 2026-02-06 | Jorgensen Nathan D. Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,500 150,500 owned after | $3.68 exercise price | $3.68 | 2026-02-10 |
| 2026-01-06 | Shiferman Gregory L. Officer (SVP and General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $4.02 exercise price | $4.02 | 2026-01-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |